28th Apr 2020 17:09
(Alliance News) - Omega Diagnostics Group PLC on Tuesday said it signed a supply agreement for its HIV testing product.
The supply pact for Visitect, with Boston-based Clinton Health Access Initiative Inc, will "accelerate access" to countries classed as low income, lower-middle income and higher-middle income by the World Bank.
"The Visitect CD4 advanced disease test is the only currently available handheld lateral flow point of care test for identifying patients with advanced HIV who are at risk of potentially life-threatening opportunistic infections," Omega Diagnostics, an allergy testing firm, said.
The agreement with Clinton Health runs to December 31, 2021.
Omega Chief Executive Officer Colin King said: "We are pleased that Omega has been able to enter into this supply agreement with CHAI, who have been very supportive towards accelerating the availability of our Visitect CD4 advanced disease. This test will help support the healthcare needs of the many people in those countries that are most in need."
Shares in the company closed 5.8% lower at 57.00 pence each in London on Tuesday.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ODX.L